New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg - film coated tablet - 500 mg - active: valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - valaciclovir hydrochloride 1112mg equivalent to valaciclovir 1000 mg;   - film coated tablet - 1000 mg - active: valaciclovir hydrochloride 1112mg equivalent to valaciclovir 1000 mg   excipient: carnauba wax colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white ys1-18043 povidone purified water - · valtrex is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - valaciclovir hydrochloride 278mg equivalent to valaciclovir 250 mg;  ; valaciclovir hydrochloride 278mg equivalent to valaciclovir 250 mg - film coated tablet - 250 mg - active: valaciclovir hydrochloride 278mg equivalent to valaciclovir 250 mg   excipient: carnauba wax colloidal silicon dioxide crospovidone edible ink blue brilliant 5312 magnesium stearate microcrystalline cellulose opadry white oy-s-28861 povidone purified water   active: valaciclovir hydrochloride 278mg equivalent to valaciclovir 250 mg excipient: carnauba wax colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white oy-s-28861 povidone purified water   - valtrex is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 584 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; titanium dioxide; colloidal anhydrous silica; hypromellose; stearic acid; macrogol 8000 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride monohydrate, quantity: 1168 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; stearic acid; macrogol 8000; titanium dioxide - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. . for the treatment of ophthalmic zoster. . for the treatment of recurrent herpes labialis (cold sores) . for the treatment of clinical episodes of genital herpes simplex infections. . for the prevention of recurrent genital herpes in immunocompromised patients. . prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - valaciclovir hydrochloride hydrate, quantity: 556.275 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of >15ml/min. prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - valaciclovir - film-coated tablet - 500 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valaciclovir

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - valaciclovir hydrochloride monohydrate - film coated tablet - 500 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - valaciclovir hydrochloride monohydrate - film coated tablet - 500 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 1112 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; carnauba wax; colour - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valtrex, it is recommended that patients use safer sex practices. (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.